摘要 |
<p>Compounds of general formula (1) and pharmacologically acceptable salts and prodrugs thereof: Formula(1) wherein A and B are CH<SUB>2</SUB> or CH<SUB>2</SUB>CH<SUB>2</SUB>, R1 is hydrogen, alkyl, cycloalkyl, aryl, aralkyl or heteroaralkyl, R2, R3 and R4 are selected from hydrogen, alkyl, halogen, haloalkyl, alkoxy, alkoxycarbonyl, carboxyl, hydroxyl or cyano; X is R5CO, R5SO<SUB>2</SUB>, R5R7NCO, R5R7NSO<SUB>2</SUB>, R5SO<SUB>2</SUB>NR7CO or CO<SUB>2</SUB>R8, Y is R6CO, R6SO<SUB>2</SUB>, R6R7NCO, R6R7NSO<SUB>2</SUB>, R6SO<SUB>2</SUB>NR7CO or CO<SUB>2</SUB>R8, R5 and R6 are hydrogen, alkyl, aryl, aralkyl, heteroaryl or heteroaralkyl, R7 is hydrogen, alkyl, aryl or aralkyl, and R8 is alkyl, aryl, aralkyl, alkoxyalkyl, heteroaryl or heteroarylalkyl, are of use in the prophylaxis or treatment of diseases and conditions in which Kv1.x channels are involved, such as lower urinary tract disorders, cardiovascular diseases and pain.</p> |
申请人 |
LECTUS THERAPEUTICS LIMITED;LAWTON, GEOFF;KOZLOWSKI, ROLAND;HOGG, DAYLE |
发明人 |
LAWTON, GEOFF;KOZLOWSKI, ROLAND;HOGG, DAYLE |